Managed Healthcare Executive February 19, 2024
Amtagvi was approved to treat patients with advanced melanoma. It is a one-time cell therapy that will be administered at authorized treatment centers and have a wholesale acquisition cost of $515,000.
The FDA has granted accelerated approval for Amtagvi (lifileucel) to treat patients with advanced melanoma. Developed by Iovance Biotherapeutics, Amtagvi is the first approved tumor-infiltrating lymphocyte (TIL) therapy designed for patients with advanced melanoma who have experienced progression after previous treatment. It is indicated for those patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. Amtagvi is a one-time therapy that requires a patient’s cancer-fighting cells to be collected so...
Today's Sponsors
Today's Sponsor